Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
12.60
-0.01 (-0.08%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
3
4
5
6
Next >
U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
January 16, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
December 21, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
December 15, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners
December 05, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases
November 27, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
November 09, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
November 08, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting
November 07, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance
October 26, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
October 18, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire
October 17, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
October 17, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda’s Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years
October 03, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Provides Update on EXKIVITY® (mobocertinib)
October 02, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
September 29, 2023
— Third major market authorization application based on data from the FRESCO-2 global Phase III trial —
From
HUTCHMED (China) Limited
Via
GlobeNewswire
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
September 27, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
September 25, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)
September 20, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Commits Over $30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 Countries
September 13, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
September 13, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis
September 11, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch Products
July 27, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1
July 26, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
June 25, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
June 20, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet
June 15, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The Lancet
June 15, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
June 15, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda to Present Oncology Portfolio and Pipeline Data at the 2023 ASCO Annual Meeting and EHA Congress
May 26, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
May 25, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.